Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

Thorax. Published Online First: 4 February 2008. doi:10.1136/thx.2007.085993
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Jensen, D.
Right arrow Articles by O'Donnell, D. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, D.
Right arrow Articles by O'Donnell, D. E.

Papers

Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD

Dennis Jensen 1, Kayvan Amjadi 1, Veronica Harris-McAllister 1, Katherine A. Webb 1 and Denis E. O'Donnell 1*

1 Queen's University, Canada

* To whom correspondence should be addressed. E-mail: odonnell{at}queensu.ca.

Accepted 16 January 2008


*   Abstract

Objectives:This study examined the effects of inhaled furosemide on the ventilatory and perceptual response to high intensity, constant-load cycle exercise in chronic obstructive pulmonary disease (COPD).

Methods: In a randomized, double-blind, placebo-controlled, cross-over study, 20 patients with COPD (forced expiratory volume in 1 sec 45 ± 15 % predicted; mean ± SD) received either nebulized furosemide 40 mg or placebo on two separate days. Thirty minutes after each treatment, patients performed pulmonary function tests and a symptom-limited cycle exercise test at 75% of their maximum incremental work-rate. Post-dose changes in spirometry, plethysmographic lung volumes, dynamic operating lung volumes, ventilation, breathing pattern, cardiovascular function, dyspnoea intensity and exercise endurance time were compared between-treatments.

Results: After treatment with furosemide compared with placebo, dyspnoea intensity at the highest equivalent exercise time (i.e., isotime for each patient) decreased by 0.9 ± 1.0 Borg units (p<0.01), with attendant improvement in exercise endurance time by 1.65 ± 0.63 min (p<0.05). These improvements were associated with increases in dynamic inspiratory capacity, tidal volume and mean tidal expiratory flow rates at isotime (p<0.01). The eight patients who improved exercise endurance time by >1 min had greater changes in operating lung volumes (p<0.05), submaximal oxygen pulse (p<0.05) and oxygen uptake (p=0.05) compared with those who did not.

Conclusion: Our results suggest that alleviation of exertional dyspnoea after single dose furosemide inhalation in COPD is multifactorial but that improvements in dynamic ventilatory mechanics are contributory in some individuals.


Keywords: COPD, dynamic lung hyperinflation, dyspnea, exercise, furosemide







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society